Skip to contentV
Vitaspring Biomedical Co. Ltd.
V
VSBCVitaspring Biomedical Co. Ltd. Q3 2025 · 10-Q
Revenue$0.00$0.00— vs Q3 2024 Net Income-$196.29K-$196.29KN/M vs Q3 2024 EPS Diluted$0.00$0.00— vs Q3 2024 Operating Income-$117,927N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Vitaspring Biomedical Co. Ltd. · CIK 1697884 · Engraved from SEC EDGAR
derived
ended Oct 31, 2024 · filed May 6, 2026 · 552 d after period end